| Dr Kathleen M Clarke-pearson, MD | |
|
195 W Illinois Ave, Southern Pines, NC 28387-5808 | |
| (910) 692-2444 | |
| (910) 692-3651 |
| Full Name | Dr Kathleen M Clarke-pearson |
|---|---|
| Gender | Female |
| Speciality | Pediatrics |
| Location | 195 W Illinois Ave, Southern Pines, North Carolina |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1518933050 | NPI | - | NPPES |
| 8922688 | Medicaid | NC |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208000000X | Pediatrics | 31792 (North Carolina) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Dr Kathleen M Clarke-pearson, MD 195 W Illinois Ave, Southern Pines, NC 28387-5808 Ph: (910) 692-2444 | Dr Kathleen M Clarke-pearson, MD 195 W Illinois Ave, Southern Pines, NC 28387-5808 Ph: (910) 692-2444 |
News Archive
Zecotek Photonics Inc., a developer of leading-edge photonics technologies for medical, industrial and scientific markets, today announced that the Company will be attending the Nuclear Science Symposium and Medical Imaging Conference in Seoul Korea from October 27 through November 2, 2013 in Seoul, Korea.
BioDelivery Sciences International, Inc. announced that it has entered into a license and supply agreement with Kunwha Pharmaceutical Co., Ltd., for the exclusive rights to develop and commercialize BEMA Fentanyl (marketed as ONSOLIS in the U.S.) in the Republic of Korea. The agreement results in potential milestone payments to BDSI of up to $1,275,000, which includes an upfront payment of $300,000. In addition, BDSI will receive an ongoing royalty based on net sales.
Seattle Genetics, Inc. and Millennium: The Takeda Oncology Company, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, today announced positive data from a phase II clinical trial of single-agent brentuximab vedotin (SGN-35) in relapsed or refractory systemic anaplastic large cell lymphoma (ALCL). Brentuximab vedotin is an antibody-drug conjugate (ADC) targeted to CD30, a defining marker of ALCL. The data were presented today during an oral session at the 52nd American Society of Hematology (ASH) Annual Meeting in Orlando, FL.
The incidence of nut allergy is on the increase in Western societies, as is the attention it receives from the public and from the media, yet little research has been carried out on the impact of living with the condition.
While drivers tend to believe it is dangerous to text and drive, many say they can still do it safely. Now Washington State University researchers say drivers can be discouraged from the practice with public service announcements that evoke their fear of death in graphic terms.
› Verified 2 days ago
Sarah Locklear Brewington, M.D. Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 195 W Illinois Ave, Southern Pines, NC 28387 Phone: 910-692-2444 | |
Dr. Lindsey M. Bellamy, D.O. Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 195 W Illinois Ave, Southern Pines, NC 28387 Phone: 910-692-2444 | |
Sarah Elizabeth Carr, M.D. Pediatrics Medicare: Medicare Enrolled Practice Location: 195 W Illinois Ave, Southern Pines, NC 28387 Phone: 910-692-2444 | |
Dr. Joseph C Boals Iv, M.D. Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 195 W Illinois Ave, Southern Pines, NC 28387 Phone: 910-692-2444 Fax: 910-692-3651 | |
Dr. Nora C Mason, M.D. Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 195 W Illinois Ave, Southern Pines, NC 28387 Phone: 910-692-2444 Fax: 910-692-3651 | |
Jennifer M Mabry, MD Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 195 W Illinois Ave, Southern Pines, NC 28387 Phone: 910-692-2444 Fax: 910-692-3651 |